Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Abroad (travel likely)Recruiting
Conditions
Advanced Hepatocellular Carcinoma · Anti-PD1/PDL1 Antibody · Bevacizumab
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Chinese PLA hospital, Beijing, Beijing Municipality, China
Contact: Principal Investigator (Feng Duan, MD)
Study leads
Feng duan, MD
Principal Investigator
Chinese PLA General Hospital